TRANEXAMIC ACID IN THE TREATMENT OF HEAVY MENSTRUAL BLEEDING: A NARRATIVE REVIEW OF EFFICACY AND SAFETY
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6220Keywords:
Heavy Menstrual Bleeding, HMB, Tranexamic Acid, Antifibrinolytic Agents, Abnormal Uterine Bleeding, Menstrual Blood LossAbstract
Background: Heavy menstrual bleeding (HMB) is a common gynaecological problem that may substantially impair quality of life and lead to health complications. Tranexamic acid (TXA) is a non-hormonal antifibrinolytic agent used during menstruation to reduce menstrual blood loss.
Aim: This narrative review aims to summarize the role of TXA in the treatment of HMB, with particular emphasis on its mechanism of action, clinical efficacy, safety profile and limitations of the available evidence.
Methods: A literature search was conducted in PubMed and Google Scholar, primarily including publications from 2010 to April 2026. Older studies were considered when historically important or widely cited. Randomised clinical trials, observational studies, systematic reviews, meta-analyses, narrative reviews, and clinical guidelines published in English were included. Data were synthesised narratively.
Results: TXA reduces menstrual blood loss by inhibiting plasminogen activation and fibrin degradation, thereby stabilising fibrin clots within the endometrium. Oral TXA is typically used intermittently, only on days of menstrual bleeding. Evidence indicates that TXA is more effective than placebo and some pharmacological therapies in reducing menstrual blood loss and may improve bleeding-related quality of life. TXA is usually well tolerated, but thromboembolic risk should be assessed individually, especially in patients with risk factors.
Conclusions: TXA is an effective and generally well-tolerated non-hormonal treatment for HMB. It does not replace diagnostic evaluation of the underlying causes of bleeding, and treatment should be individualised according to clinical risk factors, reproductive plans, and patient preferences. Further studies should assess high-risk populations and patient-reported outcomes.
References
Bofill Rodriguez, M., Dias, S., Jordan, V., et al. (2022). Interventions for heavy menstrual bleeding: Overview of Cochrane reviews and network meta-analysis. Cochrane Database of Systematic Reviews, 2022(5), CD013180. https://doi.org/10.1002/14651858.CD013180.pub2
Ammerdorffer, A., Ferrillo, O., Mills, K., et al. (2025). The prevalence and burden of heavy menstrual bleeding, and market access barriers of medical interventions with a focus on low- and middle-income countries: A scoping review. BMC Women’s Health, 26(1), 9. https://doi.org/10.1186/s12905-025-04157-5
Munro, M. G., Mast, A. E., Powers, J. M., et al. (2023). The relationship between heavy menstrual bleeding, iron deficiency, and iron deficiency anemia. American Journal of Obstetrics and Gynecology, 229(1), 1–9. https://doi.org/10.1016/j.ajog.2023.01.017
Mansour, D., Hofmann, A., & Gemzell-Danielsson, K. (2021). A review of clinical guidelines on the management of iron deficiency and iron-deficiency anemia in women with heavy menstrual bleeding. Advances in Therapy, 38(1), 201–225. https://doi.org/10.1007/s12325-020-01564-y
Munro, M. G., Critchley, H. O. D., Fraser, I. S., & FIGO Menstrual Disorders Committee. (2018). The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. International Journal of Gynecology & Obstetrics, 143(3), 393–408. https://doi.org/10.1002/ijgo.12666
Jain, V., Munro, M. G., & Critchley, H. O. D. (2023). Contemporary evaluation of women and girls with abnormal uterine bleeding: FIGO systems 1 and 2. International Journal of Gynecology & Obstetrics, 162(Suppl. 2), 29–42. https://doi.org/10.1002/ijgo.14946
Bryant-Smith, A. C., Lethaby, A., Farquhar, C., & Hickey, M. (2018). Antifibrinolytics for heavy menstrual bleeding. Cochrane Database of Systematic Reviews, 2018(4), CD000249. https://doi.org/10.1002/14651858.CD000249.pub2
Jain, V., Chodankar, R. R., Maybin, J. A., & Critchley, H. O. D. (2022). Uterine bleeding: How understanding endometrial physiology underpins menstrual health. Nature Reviews Endocrinology, 18(5), 290–308. https://doi.org/10.1038/s41574-021-00629-4
Critchley, H. O. D., Maybin, J. A., Armstrong, G. M., & Williams, A. R. W. (2020). Physiology of the endometrium and regulation of menstruation. Physiological Reviews, 100(3), 1149–1179. https://doi.org/10.1152/physrev.00031.2019
Maybin, J. A., Murray, A. A., Saunders, P. T. K., Hirani, N., Carmeliet, P., & Critchley, H. O. D. (2018). Hypoxia and hypoxia inducible factor-1α are required for normal endometrial repair during menstruation. Nature Communications, 9(1), 295. https://doi.org/10.1038/s41467-017-02375-6
Maybin, J. A., & Critchley, H. O. (2016). Medical management of heavy menstrual bleeding. Women’s Health, 12(1), 27–34. https://doi.org/10.2217/whe.15.100
Maybin, J. A., Boswell, L., Young, V. J., Duncan, W. C., & Critchley, H. O. D. (2017). Reduced transforming growth factor-β activity in the endometrium of women with heavy menstrual bleeding. The Journal of Clinical Endocrinology & Metabolism, 102(4), 1299–1308. https://doi.org/10.1210/jc.2016-3437
Cai, J., Ribkoff, J., Olson, S., et al. (2020). The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. European Journal of Haematology, 104(2), 79–87. https://doi.org/10.1111/ejh.13348
Hrometz, S. L. (2012). Oral modified-release tranexamic acid for heavy menstrual bleeding. The Annals of Pharmacotherapy, 46(7–8), 1047–1053. https://doi.org/10.1345/aph.1R025
Freeman, E. W., Lukes, A., VanDrie, D., Mabey, R. G., Gersten, J., & Adomako, T. L. (2011). A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology, 205(4), 319.e1–319.e7. https://doi.org/10.1016/j.ajog.2011.05.015
Leminen, H., & Hurskainen, R. (2012). Tranexamic acid for the treatment of heavy menstrual bleeding: Efficacy and safety. International Journal of Women’s Health, 4, 413–421. https://doi.org/10.2147/IJWH.S13840
Lukes, A. S., Moore, K. A., Muse, K. N., et al. (2010). Tranexamic acid treatment for heavy menstrual bleeding: A randomized controlled trial. Obstetrics & Gynecology, 116(4), 865–875. https://doi.org/10.1097/AOG.0b013e3181f20177
James, A. H. (2016). Heavy menstrual bleeding: Work-up and management. Hematology American Society of Hematology Education Program, 2016(1), 236–242. https://doi.org/10.1182/asheducation-2016.1.236
Samuelson Bannow, B. (2020). Management of heavy menstrual bleeding on anticoagulation. Hematology American Society of Hematology Education Program, 2020(1), 533–537. https://doi.org/10.1182/hematology.2020000138
Relke, N., Chornenki, N. L. J., & Sholzberg, M. (2021). Tranexamic acid evidence and controversies: An illustrated review. Research and Practice in Thrombosis and Haemostasis, 5(5), e12546. https://doi.org/10.1002/rth2.12546
Meaidi, A., Mørch, L., Torp-Pedersen, C., & Lidegaard, O. (2021). Oral tranexamic acid and thrombosis risk in women. EClinicalMedicine, 35, 100882. https://doi.org/10.1016/j.eclinm.2021.100882
Lim, M. Y., Olson, L., Rajpurkar, M. A., & Weyand, A. C. (2021). Concomitant use of combined hormonal contraceptives and antifibrinolytic agents for the management of heavy menstrual bleeding: A practice pattern survey. Thrombosis Research, 204, 95–100. https://doi.org/10.1016/j.thromres.2021.06.006
Lukes, A. S., Baker, J., Eder, S., & Adomako, T. L. (2012). Daily menstrual blood loss and quality of life in women with heavy menstrual bleeding. Women’s Health, 8(5), 503–511. https://doi.org/10.2217/whe.12.36
Bofill Rodriguez, M., Lethaby, A., & Farquhar, C. (2019). Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database of Systematic Reviews, 2019(9), CD000400. https://doi.org/10.1002/14651858.CD000400.pub4
Bofill Rodriguez, M., Lethaby, A., Low, C., & Cameron, I. T. (2019). Cyclical progestogens for heavy menstrual bleeding. Cochrane Database of Systematic Reviews, 2019(8), CD001016. https://doi.org/10.1002/14651858.CD001016.pub3
Bofill Rodriguez, M., Lethaby, A., & Jordan, V. (2020). Progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database of Systematic Reviews, 2020(6), CD002126. https://doi.org/10.1002/14651858.CD002126.pub4
Chen, S., Liu, J., Peng, S., & Zheng, Y. (2022). LNG-IUS vs. medical treatments for women with heavy menstrual bleeding: A systematic review and meta-analysis. Frontiers in Medicine, 9, 948709. https://doi.org/10.3389/fmed.2022.948709
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Aleksandra Papuga, Makary Hejduk, Justyna Bury, Magdalena Grzymek, Martyna Więcławek, Katarzyna Kraska, Aneta Sobek, Joanna Kadłuczka, Jan Potoniec, Weronika Kępa, Aleksandra Pawłucka, Katarzyna Pawłucka
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
